Immunicom, Inc.

About

Immunicom, Inc. is a biotechnology company based in California, founded in 2013 by Amir Jafri. The company specializes in innovative immunotherapies through its proprietary Immunopheresis™ platform, which is a blood-filtering device designed to remove immune-suppressing barriers from blood. This technology aims to treat various conditions, including cancer, inflammatory diseases, cardiovascular issues, renal diseases, and autoimmune disorders. Immunicom has made significant strides in the field of immunotherapy, receiving FDA Breakthrough Device Designation in 2018 for cancer treatment and CE Mark approval in Europe for advanced, refractory triple-negative breast cancer. The company is actively conducting global clinical trials in partnership with leading hospitals and has a robust pipeline that includes products like LW-02 and the EN-06 cartridge, targeting a range of cancers and diseases. Through its research and development efforts, Immunicom is committed to improving patients' quality of life and expediting their path to recovery.